A phase II trial of tideglusib in Alzheimer's disease

Manuscript Number: 

14-1959R1

Author(s): 
Maria V. Andres, Mercè Boada, Miguel Calero, Bruno Dubois, Belen Gomez-Carrillo, Hans-Jurgen Huppertz, Michael Hüll, Teresa Leon, Simon Lovestone, Juha O. Rinne, Teodoro del Ser

Disclosures

Maria V. Andres

  • Equity:
    Hold ordinary shares of Noscira and Zeltia, the major shareholder of Noscira
    Sponsors:
    I was employed by Noscira at that moment.

Mercè Boada

  • Consulting Fees:
    Dr. M. Boada has consulted for Lilly, Servier, Nutricia, Roche, Neuroptix, Janssen/Pfizer, Elan, Grifols, Bayer, Araclon and Avid.
    Lecture Fees:
    Fees for lectures and funds for research from Esteve, Novartis, Nutricia, Roche, Janssen, Servier, Grifols, Piramal and Araclon.
    Grants
    • Agency: 
      EFSD - European Foundation for the Study of Diabetes. EFSD/Lilly Mental Health and Diabetes Programme.
      Dates: 
      2014

Miguel Calero

  • Grants
    • Agency: 
      NOSCIRA
      Dates: 
      January 2008-December 2012

Teodoro del Ser

  • Equity:
    Teodoro del Ser holds ordinary shares of Noscira and Zeltia, the major shareholder of Noscira
    Sponsors:
    Former Medical Director

Bruno Dubois

  • Consulting Fees:
    Eli Lilly
    Grants
    • Agency: 
      Pfizer
      Dates: 
      2012

Belen Gomez-Carrillo

  • Equity:
    I hold ordinary shares of Zeltia, the major shareholder of Noscira
    Sponsors:
    Former project manager of Noscira. Not working there anymore since December 2012.

Michael Hüll

  • Consulting Fees:
    paid advisory board for Hoffmann-LaRoche

Hans-Jurgen Huppertz

  • Nothing to Disclose

Teresa Leon

  • Equity:
    Zeltia
    Sponsors:
    I was an employee of Noscira at the time the trial was planned and run. Noscira is not a commercial entity as it had no products in the market. Noscira was a research entity.

Simon Lovestone

  • Consulting Fees:
    Fee of €1000 for membership of Lundbeck Neuroscience Institute
    Patents/Royalties
    named as inventor on patents for biomarkers held by KCL and Proteome Sciences
    Grants
    • Agency: 
      J&J/GE
      Dates: 
      2012-2014
    • Agency: 
      Multiple EFPIA companies via IMI
      Dates: 
      2010-2018
    • Agency: 
      GSK via MRC CASE award
      Dates: 
      2011-2015

Juha O. Rinne

  • Consulting Fees:
    J Rinne serves as a consultant for TEVA Finland Ltd and Clinical Research Services Turku (CRST) Ltd